Mirum Pharmaceuticals Inc’s recently made public that its Director Fairey William unloaded Company’s shares for reported $0.16 million on Jun 11 ’25. In the deal valued at $48.42 per share,3,203 shares were sold. As a result of this transaction, Fairey William now holds 2,500 shares worth roughly $0.12 million.
Then, WILLIAM C FAIREY bought 3,203 shares, generating $155,091 in total proceeds.
Before that, Ramasastry Saira sold 5,703 shares. Mirum Pharmaceuticals Inc shares valued at $263,492 were divested by the Director at a price of $46.20 per share. As a result of the transaction, Ramasastry Saira now holds 0 shares, worth roughly $0.0.
A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in mid April with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering MIRM and reiterated its “Buy” recommendation on December 18, 2023.
Price Performance Review of MIRM
On Tuesday, Mirum Pharmaceuticals Inc [NASDAQ:MIRM] saw its stock fall -4.91% to $48.39. Over the last five days, the stock has lost -5.32%. Mirum Pharmaceuticals Inc shares have risen nearly 46.15% since the year began. Nevertheless, the stocks have risen 17.03% over the past one year. While a 52-week high of $54.23 was reached on 02/21/25, a 52-week low of $33.45 was recorded on 04/09/25.
Levels Of Support And Resistance For MIRM Stock
The 24-hour chart illustrates a support level at 47.51, which if violated will result in even more drops to 46.64. On the upside, there is a resistance level at 49.99. A further resistance level may holdings at 51.59.
How much short interest is there in Mirum Pharmaceuticals Inc?
A steep rise in short interest was recorded in Mirum Pharmaceuticals Inc stocks on 2025-06-13, dropping by 68863.0 shares to a total of 6.22 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.29 million shares. There was a decline of -1.11%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 13, 2023 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
